These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

231 related articles for article (PubMed ID: 27388750)

  • 1. A cost effective analysis of fixed-dose combination of dutasteride and tamsulosin compared with dutasteride monotherapy for benign prostatic hyperplasia in Nigeria: a middle income perspective; using an interactive Markov model.
    Udeh EI; Ofoha CG; Adewole DA; Nnabugwu II
    BMC Cancer; 2016 Jul; 16():405. PubMed ID: 27388750
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cost-effectiveness of single-dose tamsulosin and dutasteride combination therapy compared with tamsulosin monotherapy in patients with benign prostatic hyperplasia in the UK.
    Walker A; Doyle S; Posnett J; Hunjan M
    BJU Int; 2013 Sep; 112(5):638-46. PubMed ID: 23356792
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cost effectiveness comparison of dutasteride and finasteride in patients with benign prostatic hyperplasia--The Markov model based on data from Montenegro.
    Dabanović V; Kostić M; Janković S
    Vojnosanit Pregl; 2016 Jan; 73(1):26-33. PubMed ID: 26964381
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cost-effectiveness of combination therapy for treatment of benign prostatic hyperplasia: a model based on the findings of the Combination of Avodart and Tamsulosin trial.
    Bjerklund Johansen TE; Baker TM; Black LK
    BJU Int; 2012 Mar; 109(5):731-8. PubMed ID: 21933326
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The effects of combination therapy with dutasteride and tamsulosin on clinical outcomes in men with symptomatic benign prostatic hyperplasia: 4-year results from the CombAT study.
    Roehrborn CG; Siami P; Barkin J; Damião R; Major-Walker K; Nandy I; Morrill BB; Gagnier RP; Montorsi F;
    Eur Urol; 2010 Jan; 57(1):123-31. PubMed ID: 19825505
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical outcomes after combined therapy with dutasteride plus tamsulosin or either monotherapy in men with benign prostatic hyperplasia (BPH) by baseline characteristics: 4-year results from the randomized, double-blind Combination of Avodart and Tamsulosin (CombAT) trial.
    Roehrborn CG; Barkin J; Siami P; Tubaro A; Wilson TH; Morrill BB; Gagnier RP
    BJU Int; 2011 Mar; 107(6):946-54. PubMed ID: 21332630
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dutasteride plus tamsulosin fixed-dose combination first-line therapy versus tamsulosin monotherapy in the treatment of benign prostatic hyperplasia: a budget impact analysis in the Greek healthcare setting.
    Geitona M; Karabela P; Katsoulis IA; Kousoulakou H; Lyberopoulou E; Bitros E; Xaplanteris L; Papanicolaou S
    BMC Urol; 2014 Sep; 14():78. PubMed ID: 25255740
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cost-Effectiveness of Combination Therapy Versus Monotherapy in Benign Prostatic Hyperplasia: A Colombian Experience.
    Guevara-Cuellar CA; Parody-Rúa E; Garcia-Perdomo HA; Arenas-Duque A
    Value Health Reg Issues; 2018 Dec; 17():174-182. PubMed ID: 30415110
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Influence of baseline variables on changes in International Prostate Symptom Score after combined therapy with dutasteride plus tamsulosin or either monotherapy in patients with benign prostatic hyperplasia and lower urinary tract symptoms: 4-year results of the CombAT study.
    Roehrborn CG; Barkin J; Tubaro A; Emberton M; Wilson TH; Brotherton BJ; Castro R
    BJU Int; 2014 Apr; 113(4):623-35. PubMed ID: 24127818
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Cost-effectiveness of the combination therapy of dutasteride and tamsulosin in the treatment of benign prostatic hyperlasia in Spain].
    Antoñanzas F; Brenes F; Molero JM; Fernández-Pro A; Huerta A; Palencia R; Cozar JM
    Actas Urol Esp; 2011 Feb; 35(2):65-71. PubMed ID: 21269736
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The long-term cost effectiveness of treatments for benign prostatic hyperplasia.
    DiSantostefano RL; Biddle AK; Lavelle JP
    Pharmacoeconomics; 2006; 24(2):171-91. PubMed ID: 16460137
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cost-effectiveness of a fixed-dose combination of solifenacin and oral controlled adsorption system formulation of tamsulosin in men with lower urinary tract symptoms associated with benign prostatic hyperplasia.
    Nazir J; Heemstra L; van Engen A; Hakimi Z; Ivanescu C
    BMC Urol; 2015 May; 15():41. PubMed ID: 25956727
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The influence of baseline parameters on changes in international prostate symptom score with dutasteride, tamsulosin, and combination therapy among men with symptomatic benign prostatic hyperplasia and an enlarged prostate: 2-year data from the CombAT study.
    Roehrborn CG; Siami P; Barkin J; Damião R; Becher E; Miñana B; Mirone V; Castro R; Wilson T; Montorsi F;
    Eur Urol; 2009 Feb; 55(2):461-71. PubMed ID: 19013011
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Cost-effectiveness model of a fixed dose combination of solifenacin and tamsulosin for the treatment of LUTS associated with BPH with inadequate response to monotherapy.].
    Alcántara A; Cózar JM; Errando C; Rubio-Rodríguez D; Rubio-Rodríguez D; Rubio-Terrés C; Mora AM; Duran A
    Arch Esp Urol; 2018 Sep; 71(7):595-606. PubMed ID: 30198851
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and safety of a fixed-dose combination of dutasteride and tamsulosin treatment (Duodart(®) ) compared with watchful waiting with initiation of tamsulosin therapy if symptoms do not improve, both provided with lifestyle advice, in the management of treatment-naïve men with moderately symptomatic benign prostatic hyperplasia: 2-year CONDUCT study results.
    Roehrborn CG; Oyarzabal Perez I; Roos EP; Calomfirescu N; Brotherton B; Wang F; Palacios JM; Vasylyev A; Manyak MJ
    BJU Int; 2015 Sep; 116(3):450-9. PubMed ID: 25565364
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cost-effectiveness of tamsulosin, doxazosin, and terazosin in the treatment of benign prostatic hyperplasia.
    Ohsfeldt RL; Kreder KJ; Klein RW; Chrischilles EA
    J Manag Care Pharm; 2004; 10(5):412-22. PubMed ID: 15369424
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of dutasteride, tamsulosin and the combination on patient-reported quality of life and treatment satisfaction in men with moderate-to-severe benign prostatic hyperplasia: 4-year data from the CombAT study.
    Montorsi F; Henkel T; Geboers A; Mirone V; Arrosagaray P; Morrill B; Black L
    Int J Clin Pract; 2010 Jul; 64(8):1042-51. PubMed ID: 20487046
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Superiority of dutasteride 0.5 mg and tamsulosin 0.2 mg for the treatment of moderate-to-severe benign prostatic hyperplasia in Asian men.
    Haque N; Masumori N; Sakamoto S; Ye Z; Yoon SJ; Kuo HC; Brotherton B; Wilson T; Muganurmath C; McLaughlin M; Manyak M
    Int J Urol; 2018 Nov; 25(11):944-951. PubMed ID: 30198102
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cost-effectiveness of dutasteride-tamsulosin combination therapy for the treatment of symptomatic benign prostatic hyperplasia: A Canadian model based on the CombAT trial.
    Ismaila A; Walker A; Sayani A; Laroche B; Nickel JC; Posnett J; Su Z
    Can Urol Assoc J; 2013; 7(5-6):E393-401. PubMed ID: 23826050
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of the response to treatment between Asian and Caucasian men with benign prostatic hyperplasia: long-term results from the combination of dutasteride and tamsulosin study.
    Chung BH; Lee SH; Roehrborn CG; Siami PF; Major-Walker K; Wilson TH; Montorsi F;
    Int J Urol; 2012 Nov; 19(11):1031-5. PubMed ID: 22774774
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.